RCTNCT00154401Phase 2 · 2005 · n=177 · Novo Nordisk A/S Diabetes
tested HbA1c
result Completed; results not posted
RCTNCT00154414Phase 2 · 2005 · n=226 · Novo Nordisk A/S Diabetes
tested HbA1c
result Completed; results not posted
RCTNCT00294723Phase 3 · 2006 · n=746 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52
result Terminated before completion
Terminated: The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power
RCTNCT00318422Phase 3 · 2006 · n=1041 · Novo Nordisk A/S Diabetes
tested HbA1c
result Completed; results not posted
RCTNCT00318461Phase 3 · 2006 · n=1091 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated A1c (HbA1c) at Week 26
RCTNCT00331851Phase 3 · 2006 · n=584 · Novo Nordisk A/S Diabetes
tested HbA1c
result Completed; results not posted
RCTNCT00333151Phase 3 · 2006 · n=576 · Novo Nordisk A/S Diabetes
tested HbA1c
result Completed; results not posted
RCTNCT00393718Phase 3 · 2006 · n=400 · Novo Nordisk A/S Diabetes
tested Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
result −0.5 percentage of total haemoglobin (Glycosylated Haemoglobin A1c (HbA1c) After 24 Week…)
RCTNCT00395746Phase 3 · 2006 · n=264 · Novo Nordisk A/S Diabetes
tested Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
RCTNCT00422058Phase 2 · 2007 · n=564 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Mean Change From Baseline in Body Weight at Week 20
result +0.2 kg (Mean Change From Baseline in Body Weight at Week 2…)
RCTNCT00518882Phase 3 · 2007 · n=467 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated A1c (HbA1c) at Week 26
result −0.3 percentage point of total HbA1c (Change in Glycosylated A1c (HbA1c) at Week 26)
RCTNCT00614120Phase 3 · 2008 · n=929 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin A1c (HbA1c)
Diabetes
tested Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)
RCTNCT00696657Phase 2 · 2008 · n=415 · Novo Nordisk A/S Diabetes
tested HbA1c
result −0.6 Percentage (%) of HbA1c (HbA1c)
RCTNCT00700817Phase 3 · 2008 · n=665 · Novo Nordisk A/S Diabetes
tested Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26
Pharmacokinetic / healthy volunteer studies
tested AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing.
result Completed; results not posted
RCTNCT00781937Phase 3 · 2008 · n=422 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Mean Percentage Change in Fasting Body Weight From Baseline
result −6.1 percentage (Mean Percentage Change in Fasting Body Weight From…)
RCTNCT00856986Phase 3 · 2009 · n=987 · Novo Nordisk A/S Diabetes
tested Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.
Diabetes
tested Number and type of adverse events
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Metabolism and Nutrition Disorder
tested Gastric emptying measured as AUC0-300min of paracetamol postprandial concentration profiles during a standardised meal test with intake of 1.5 g paracetamol
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT00993720Phase 2 · 2009 · n=30 · Hvidovre University Hospital Diabetes Mellitus
tested insulin-dose
result Completed; results not posted
Type 2 Diabetes Mellitus
tested Change in HbA1c From Baseline to Week 26
result −0.2 percentage of total hemoglobin (Change in HbA1c From Baseline to Week 26)
Diabetes Mellitus, Type 2
tested Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period
result −2.5 percentage of participants (Percentage of Patients Whose Glycosylated Haemoglo…)
Diabetes Mellitus, Type 2
tested Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32
result −0.2 Percentage of HbA1c in the blood (Mean Change From Baseline in Glycosylated Hemoglob…)
Type 2 Diabetes Mellitus
tested Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28
result +154 h*mg/dL (Change From Baseline in Area Under the Plasma Gluc…)
RCTNCT01179048Phase 3 · 2010 · n=9341 · Novo Nordisk A/S Diabetes
tested Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)
result −1.9 percentage of subjects (Time From Randomisation to First Occurrence of Car…)
Diabetes
tested Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant
result Terminated before completion
Terminated: The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well as challenges relating to trial execution and study completion.
Diabetes Mellitus, Type 2
tested The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells
result Completed; results not posted
Type 2 Diabetes
tested Myocardial Glucose Uptake
Gestational Diabetes Mellitus
tested Insulin Secretion-Sensitivity Index (IS-SI)
result +85.4 index (Insulin Secretion-Sensitivity Index (IS-SI))
RCTNCT01237119Phase 2 · 2010 · n=52 · University of Birmingham NAFLD / steatotic liver disease — hepatic fat reduction
tested Liver Histological improvement
result Completed; results not posted
RCTNCT01270789Phase 3 · 2011 · n=63 · Mount Sinai Hospital, Canada Type 2 Diabetes
tested Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2)
result Completed; results not posted
RCTNCT01272219Phase 3 · 2011 · n=3731 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Change From Baseline in Fasting Body Weight
result −5.4 percent change (Change From Baseline in Fasting Body Weight)
RCTNCT01272232Phase 3 · 2011 · n=846 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Change (%) From Baseline in Body Weight (Fasting)
result −3.9 percent change (Change (%) From Baseline in Body Weight (Fasting))
RCTNCT01296412Phase 3 · 2011 · n=653 · Merck Sharp & Dohme LLC Diabetes Mellitus, Type 2
tested Change From Baseline in Hemoglobin A1c (A1C)
result −0.1 percent (Change From Baseline in Hemoglobin A1c (A1C))
Pharmacokinetic / healthy volunteer studies
tested The area under insulin degludec concentration-time curve
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01336023Phase 3 · 2011 · n=1663 · Novo Nordisk A/S Diabetes
tested Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.
RCTNCT013636092011 · n=50 · Amsterdam UMC, location VUmc Obesity
tested food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%)
result Completed; results not posted
RCTNCT01373450Phase 1 · 2011 · n=12 · Merck Sharp & Dohme LLC Type 2 Diabetes Mellitus
tested Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)
result −16.3 mg/dL (Change From Baseline in Time-weighted Average of G…)
Small sample; effect at the edge of clinical significance.
RCTNCT01388361Phase 3 · 2011 · n=413 · Novo Nordisk A/S Diabetes
tested Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)
RCTNCT01392573Phase 3 · 2011 · n=413 · Novo Nordisk A/S Diabetes
tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)
RCTNCT013928982012 · n=50 · Radboud University Medical Center Type 2 Diabetes Mellitus
tested Body weight change (measured body weight at 26 weeks minus baseline body weight)
result In progress (unknown)
RCTNCT01394341Phase 4 · 2011 · n=40 · Bo Feldt-Rasmussen Type 2 Diabetes Mellitus
tested Plasma liraglutide concentration (pmol/L)
result Completed; results not posted
RCTNCT01399645Phase 2 · 2011 · n=35 · Centre hospitalier de l'Université de Montréal (CHUM) NAFLD / steatotic liver disease — hepatic fat reduction
tested To determine liver fat fraction evolution induced by liraglutide and insulin
result Completed; results not posted
Congestive Heart Failure
tested Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography
result Completed; results not posted
RCTNCT014519052011 · n=12 · University Hospital, Gentofte, Copenhagen Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
tested Changes in PASI and DLQI
result In progress (unknown)
Psoriasis
tested PASI (psoriasis area and severity index)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Alzheimers Disease
tested PIB PET scan
result Completed; results not posted
Hyperglycemia
tested Change in Left ventricular function from visit 1 to week 24, measured by Ecco
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Number of Treatment Emergent Adverse Events (TEAEs)
Type 2 Diabetes Mellitus
tested Glycemic Control Measured by HbA1c
result −1.0 Percent HbA1c (Glycemic Control Measured by HbA1c)
Pharmacokinetic / healthy volunteer studies
tested AUC (area under the curve)
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Area under the Curve
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested Insulin secretory burst mass
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested AUC of ethinylestradiol
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Pharmacokinetic / healthy volunteer studies
tested Area under the Curve (AUC) (0-t)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested 24-hour glucose profiles after three fixed meals
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested Change in weight
result Completed; results not posted
Diabetes
tested Area under the Curve (AUC) glucagon
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Pharmacokinetic / healthy volunteer studies
tested Ratio of the areas under the plasma NN 90-1170 curves
result Completed; results not posted
RCTNCT01511172Phase 2 · 2002 · n=145 · Novo Nordisk A/S Diabetes
tested Fasting plasma/serum glucose
result Completed; results not posted
Diabetes
tested AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01511198Phase 2 · 2001 · n=223 · Novo Nordisk A/S Diabetes
tested Body weight
result Completed; results not posted
Diabetes
tested The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10
result Completed; results not posted
RCTNCT01512108Phase 3 · 2012 · n=363 · Novo Nordisk A/S Diabetes
tested Incidence of Treatment Emergent Adverse Events (AEs)
result +30.0 Events/100 years of patient exposure (Incidence of Treatment Emergent Adverse Events (AE…)
Pharmacokinetic / healthy volunteer studies
tested Area under the Curve (AUC) of liraglutide for each injection site
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Pharmacokinetic / healthy volunteer studies
tested Area under the Curve (0-t)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Pharmacokinetic / healthy volunteer studies
tested Area under the curve (0-t)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Pharmacokinetic / healthy volunteer studies
tested Area under the curve (0-t)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested Adverse events
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Diabetes
tested Maximum time-matched mean difference between the baseline subtracted QTci intervals
result Completed; results not posted
Diabetes Mellitus Type 2
tested Change in hemoglobin A1c (HA1c)
result Terminated before completion
Diabetes
tested Area under the curve of paracetamol
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01518101Phase 4 · 2012 · n=62 · Novartis Pharmaceuticals Type 2 Diabetes
tested Proportion of patients preferring each treatment regimen
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Area under the curve of atorvastatin
result Completed; results not posted
Diabetes
tested Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) )
result Completed; results not posted
RCTNCT01541215Phase 3 · 2012 · n=135 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Glycosylated Haemoglobin)
result −1.1 Percentage of HbA1c (Change in HbA1c (Glycosylated Haemoglobin))
RCTNCT01550653Phase 1 · 2012 · n=40 · University of Luebeck Pharmacokinetic / healthy volunteer studies
tested Change from Baseline in the immediate and delayed recall of a declarative memory task (word list recall) at time points indicated in "time frame" section.
result Completed; results not posted
RCTNCT01557166Phase 3 · 2012 · n=359 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Change From Baseline in Apnoea-hypopnoea Index (AHI)
result −6.1 events/hour (Change From Baseline in Apnoea-hypopnoea Index (AH…)
RCTNCT01558271Phase 3 · 2012 · n=492 · Eli Lilly and Company Type 2 Diabetes Mellitus
tested Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
result −1.5 percentage of HbA1c (Change From Baseline in Glycosylated Hemoglobin (H…)
RCTNCT01562678Phase 4 · 2012 · n=28 · Beth Israel Deaconess Medical Center Diabetes
tested Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization
result −0.9 z-scores of activation in cortex (Change Between Highly Desirable vs. Less Desirable…)
Small sample; effect at the edge of clinical significance.
RCTNCT01572740Phase 3 · 2012 · n=257 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16
result −1.3 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)
RCTNCT01592279Phase 4 · 2012 · n=124 · Hadassah Medical Organization Uncontrolled Type 1 Diabetic Patients
tested The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline.
result In progress (unknown)
RCTNCT01593137Phase 4 · 2012 · Fundación Fernández-Cruz Type 2 Diabetes
tested assess the effect of treatment with liraglutide compared to glimepiride, as add-on to metformin, for one year on circulating levels of EPCs in patients with type 2 diabetes poorly controlled.
result Withdrawn before enrolment
Withdrawn: Lack of patients with the criteria established in the protocol.
RCTNCT01595789Phase 4 · 2012 · n=41 · Haugaard, Steen Bendix, M.D., DMSc Coronary Artery Disease
tested Beta-cell function
result Completed; results not posted
Type 2 Diabetes Mellitus
tested Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours
RCTNCT01597531Phase 4 · 2012 · n=1 · East Carolina University Type 2 Diabetes
tested Type 2 diabetes remission
result Terminated before completion
Terminated: Difficulty recruiting patients
RCTNCT01610934Phase 2 · 2012 · n=15 · University Hospital, Gentofte, Copenhagen Maturity-onset Diabetes of the Young
tested Fasting Plasma Glucose
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01612468Phase 4 · 2012 · n=100 · Steno Diabetes Center Copenhagen Diabetes Mellitus, Type 1
tested Change in HbA1c
result Completed; results not posted
Diabetes
tested 24-hour profiles of serum calcitonin
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01617434Phase 3 · 2012 · n=451 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26
result −1.2 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)
RCTNCT01618162Phase 3 · 2012 · n=435 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c)
result −1.0 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c))
Diabetes
tested Body weight
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Area under the plasma liraglutide curve
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01620489Phase 3 · 2012 · n=279 · Novo Nordisk A/S Diabetes
tested Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)
result −0.7 percentage (%) (Estimated Mean From the Statistical Model and Stan…)
RCTNCT01624259Phase 3 · 2012 · n=599 · Eli Lilly and Company Type 2 Diabetes
tested Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
result +0.1 percentage of glycosylated hemoglobin (Change From Baseline to 26 Weeks Endpoint in Glyco…)
RCTNCT01628445Phase 3 · 2012 · n=52 · University of Manitoba Type 2 Diabetes
tested Change in A1c
result Terminated before completion
Terminated: Error made by local pharmacy caused mixed randomization of 20 participants
RCTNCT01638260Phase 4 · 2012 · n=22 · Maastricht University Medical Center Type 2 Diabetes Mellitus
tested Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)
result Terminated before completion
Terminated: Terminated because of insufficient number of subjects included.
RCTNCT01654120Phase 4 · 2011 · n=37 · Mountain Diabetes and Endocrine Center Diabetes Mellitus, Type II
tested Change from baseline in HbA1c at six months
result Completed; results not posted
RCTNCT01658501Phase 2 · 2012 · n=593 · PhaseBio Pharmaceuticals Inc. Type 2 Diabetes Mellitus
tested Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator
result Completed; results not posted
RCTNCT01664247Phase 3 · 2012 · n=346 · Novo Nordisk A/S Diabetes
tested Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
result −0.9 percentage of glycosylated haemoglobin (Change From Baseline in Glycosylated Haemoglobin (…)
RCTNCT01664676Phase 4 · 2012 · n=11 · University of Aarhus Type 2 Diabetes Mellitus
tested Glomerular Filtration Rate (51Cr-EDTA plasma clearance)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01676116Phase 3 · 2012 · n=438 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)
result −1.0 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)
RCTNCT01695109Phase 4 · 2010 · n=16 · Medical University of Vienna Healthy Human Male Subjects
tested Food intake at an ad libitum buffet
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Type 1 Diabetes
tested Mean weekly blood glucose concentrations.
result Withdrawn before enrolment
Withdrawn: No Funding Received from ADA
RCTNCT01722240Phase 3 · 2012 · n=69 · University at Buffalo Type 1 Diabetes
tested HbA1c (%)
result +0.4 Percent of Hemoglobin (%) (HbA1c (%))
RCTNCT01722266Phase 3 · 2012 · n=72 · University at Buffalo Type 1 Diabetes
tested Change in Mean Weekly Glucose Concentrations
result −11.0 mg/dl (Change in Mean Weekly Glucose Concentrations)
Obesity
tested Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death During Part A
result +7.0 Participants (Number of Participants With Any Adverse Event (AE)…)
Diabetes Mellitus, Type 2
tested Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
result −0.1 Percentage of HbA1c in the blood (Mean HbA1c at Baseline, Week 24, and Change From B…)
RCTNCT01739049Phase 4 · 2012 · n=42 · Universiti Kebangsaan Malaysia Medical Centre Binge Eating Behaviour
tested Reduction in binge eating scale score
result Completed; results not posted
RCTNCT017409212011 · n=39 · Royal Devon and Exeter NHS Foundation Trust Type 2 Diabetes
tested change of baseline skin maximum hyperaemia at 4 months
result Completed; results not posted
RCTNCT01744236Phase 4 · 2013 · n=70 · Amsterdam UMC, location VUmc Type 2 Diabetes
tested Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements.
result Completed; results not posted
RCTNCT01753362Phase 3 · 2012 · n=84 · University at Buffalo Type 1 Diabetes
tested HbA1c
result +0.2 percent (HbA1c)
RCTNCT01755416Phase 2 · 2013 · n=18 · Albert Einstein College of Medicine Type 1 Diabetes
tested Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone
result −15.1 mg/dl (Blood Glucose Measures in Subjects on Closed Loop …)
Small sample; effect at the edge of clinical significance.
RCTNCT01755572Phase 4 · 2013 · n=22 · Mount Sinai Hospital, Canada Type 2 Diabetes
tested Change in plasma ANP level at 1 Day
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01761318Phase 4 · 2013 · n=50 · Leiden University Medical Center NAFLD / steatotic liver disease — hepatic fat reduction
tested Stroke volume
result Completed; results not posted
RCTNCT01779362Phase 3 · 2013 · n=267 · RISE Study Group Prediabetes
tested ß-cell Response Measured by Hyperglycemic Clamp
result +0.1 nmol/L (ß-cell Response Measured by Hyperglycemic Clamp)
RCTNCT01782261Phase 2 · 2012 · n=15 · Medical University of Graz Type 1 Diabetes
tested Increase of regulatory FOXP3+ T cells
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01784965Phase 3 · 2009 · n=69 · Stanford University Pre-diabetes
tested Change in Weight Reported at 14 Weeks
result −3.5 kg (Change in Weight Reported at 14 Weeks)
DIABETES Mellitus Type 2 Not Well Controlled
tested Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01787916Phase 4 · 2013 · n=15 · CHU de Quebec-Universite Laval Type 1 Diabetes
tested Assessment of Changes in Glycemic Control by HbA1c.
result +0.1 percentage of HbA1c (Assessment of Changes in Glycemic Control by HbA1c…)
Small sample; effect at the edge of clinical significance.
Metabolism and Nutrition Disorder
tested Number of treatment emergent adverse events (TEAEs)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT01790308Phase 4 · 2013 · n=100 · Sun Yat-sen University Diabetes Mellitus, Type 2
tested the percentage of the patients who maintain glucose control 1 year after short intensive therapy
result In progress (unknown)
RCTNCT01794143Phase 3 · 2013 · n=7850 · GRADE Study Group Type 2 Diabetes
tested Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication
Gestational Diabetes Mellitus
tested Change in glucose tolerance
result Completed; results not posted
Acute Heart Failure
tested Global Ranking of Predefined Events
result −10.2 rank (Global Ranking of Predefined Events)
RCTNCT01836523Phase 3 · 2013 · n=1398 · Novo Nordisk A/S Diabetes
tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)
result −0.1 percentage of glycosylated haemoglobin (Change From Baseline in HbA1c (Glycosylated Haemog…)
RCTNCT01843075Phase 2 · 2014 · n=204 · Imperial College London Alzheimer's Disease
tested The change in cerebral glucose metabolic rate
result In progress (unknown)
RCTNCT01845259Phase 2 · 2013 · n=103 · Psychiatric Centre Rigshospitalet Impaired Glucose Tolerance Associated With Drugs
tested Glucose tolerance
result In progress (unknown)
Diabetic Kidney Disease
tested MCP-1:Creatinine Ratio in Urine
result +3.6 ng/mmol (MCP-1:Creatinine Ratio in Urine)
Small sample; effect at the edge of clinical significance.
RCTNCT01870297Phase 1 · 2013 · n=72 · Eli Lilly and Company Type 2 Diabetes Mellitus
tested Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
result ±0.0 participants (Number of Participants With One or More Serious Ad…)
RCTNCT01879917Phase 2 · 2014 · n=65 · Hvidovre University Hospital Diabetes Mellitus, Type 1
tested Beta-cell function
result Completed; results not posted
RCTNCT01899430Phase 4 · 2011 · n=32 · University Medical Centre Ljubljana PCOS
tested The main outcome was change in body weight.
result Completed; results not posted
RCTNCT01907854Phase 4 · 2013 · n=407 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Glycosylated Haemoglobin)
result −0.6 percentage of glycosylated haemoglobin (Change in HbA1c (Glycosylated Haemoglobin))
RCTNCT01911468Phase 4 · 2011 · n=36 · University Medical Centre Ljubljana PCOS
tested The main outcome was change in body weight.
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Area under the serum IDeg concentration time curve after single dose
result Completed; results not posted
RCTNCT01917656Phase 4 · 2014 · n=343 · Novo Nordisk A/S Diabetes
tested Change in Fructosamine From Start of Ramadan to End of Ramadan
result +1.7 umol/L (Change in Fructosamine From Start of Ramadan to En…)
RCTNCT01919489Phase 4 · 2014 · n=273 · Emory University Type 2 Diabetes
tested Glycemic Control at Hospital Discharge and 6 Months Follow up
result −0.1 % (mmol/mol) (Glycemic Control at Hospital Discharge and 6 Month…)
RCTNCT01931982Phase 4 · 2013 · n=20 · Bispebjerg Hospital Type 2 Diabetes
tested Change in coronary flow reserve (CFR)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Type 2 Diabetes
tested Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC)
result +121 [mg*min/dL] (Incremental Area Under the Plasma Glucose (BG) Con…)
Small sample; effect at the edge of clinical significance.
RCTNCT01952145Phase 3 · 2013 · n=557 · Novo Nordisk A/S Diabetes
tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)
result −0.7 Percentage (%) (Change From Baseline in HbA1c (Glycosylated Haemog…)
RCTNCT01966978Phase 4 · 2014 · n=157 · University of Texas Southwestern Medical Center Diabetes Mellitus, Type 2
tested Mean Change From Randomization in A1c at Week 26
result +0.7 Percentage of glycosylated hemoglobin (Mean Change From Randomization in A1c at Week 26)
RCTNCT01973231Phase 4 · 2013 · n=404 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline
result −0.6 Percent (%) glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)
RCTNCT01982630Phase 1 · 2013 · n=87 · Merck Sharp & Dohme LLC Diabetes Mellitus
tested Number of Participants Experiencing Adverse Events (AEs) in Part 1
result −3.0 Participants (Number of Participants Experiencing Adverse Events…)
Acute Myocardial Infarction
tested the salvage index measured by cardiac magnetic resonance
result In progress (unknown)
RCTNCT02008682Phase 4 · 2013 · n=368 · Novo Nordisk A/S Diabetes
tested Change From Baseline in Glycosylated Haemoglobin (HbA1c)
result −0.7 Percent (%) glycosylated haemoglobin (Change From Baseline in Glycosylated Haemoglobin (…)
RCTNCT02014740Phase 4 · 2014 · n=100 · University of Miami Type 2 Diabetes
tested Echocardiographic Epicardial Fat Thickness
result +2.2 mm (Echocardiographic Epicardial Fat Thickness)
RCTNCT02016846Phase 3 · 2014 · n=36 · Rabin Medical Center Glucocorticoid Induced Hyperglycemia
tested Glucose levels 2 hours after 75 gr OGTT
result In progress (unknown)
RCTNCT020363722014 · n=150 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Diabetes Mellitus Type II
tested Median glucose
result Completed; results not posted
RCTNCT02043054Phase 3 · 2013 · n=90 · University of Leicester Type 2 Diabetes Mellitus
tested Change in peak early diastolic strain rate measured by cardiac MRI
result Completed; results not posted
RCTNCT02055014Phase 4 · 2013 · n=72 · Sandwell & West Birmingham Hospitals NHS Trust Type 2 Diabetes
tested Glycated haemoglobin (HbA1c)
result In progress (unknown)
RCTNCT02057172Phase 2 · 2014 · n=254 · Hanmi Pharmaceutical Company Limited Type 2 Diabetes
tested Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks
result Completed; results not posted
RCTNCT02059564Phase 1 · 2013 · n=44 · Hanmi Pharmaceutical Company Limited Diabetes Mellitus
tested PK profile of acetaminophen
result In progress (unknown)
RCTNCT02060383Phase 4 · 2014 · n=249 · Novartis Pharmaceuticals Cushing's Disease
tested Change in HbA1c From Randomization to Approximately 16 Weeks
RCTNCT02072096Phase 4 · 2014 · n=192 · Eli Lilly and Company Diabetes Mellitus, Type 2
tested Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
result Terminated before completion
Terminated: The trial was terminated per protocol because of lack of feasibility.
Polycystic Ovary Syndrome
tested Change in Endogenous Thrombin Potential (ETP)
result −48.5 nMolar x minutes (Change in Endogenous Thrombin Potential (ETP))
RCTNCT02092896Phase 3 · 2013 · n=40 · Hvidovre University Hospital Diabetes
tested Change from baseline in HbA1c (glycosylated haemoglobin)
result Completed; results not posted
RCTNCT02098395Phase 3 · 2014 · n=835 · Novo Nordisk A/S Diabetes
tested Change From Baseline in Glycosylated Haemoglobin (HbA1c)
result −0.2 Percent (%) glycosylated haemoglobin (Change From Baseline in Glycosylated Haemoglobin (…)
Diabetes
tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Type 1 Diabetes Mellitus
tested Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.
result Withdrawn before enrolment
Withdrawn before enrolment; no public reason provided.
RCTNCT02113332Phase 2 · 2013 · n=124 · Vastra Gotaland Region Type 2 Diabetes Mellitus
tested Change in HbA1c from baseline to week 24.
result Completed; results not posted
RCTNCT021380452014 · n=39 · Aalborg University Hospital Diabetes Mellitus, Type 1
tested RIII withdrawal reflex activity (using standard electromyography)
result Completed; results not posted
RCTNCT02140983Phase 1 · 2013 · n=41 · Stanford University Insulin Resistance
tested Cognitive Outcomes
result Completed; results not posted
RCTNCT02147925Phase 4 · 2014 · n=75 · Sun Yat-sen University NAFLD / steatotic liver disease — hepatic fat reduction
tested Intrahepatic lipids (IHL)
result Completed; results not posted
RCTNCT02187250Phase 4 · 2014 · n=45 · University Medical Centre Ljubljana PCOS
tested The main outcome was change in body weight.
result Completed; results not posted
RCTNCT02205528Phase 2 · 2014 · n=108 · Novo Nordisk A/S Diabetes
tested Change in HbA1c
result Completed; results not posted
Metabolism and Nutrition Disorder
tested Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02231658Phase 1 · 2015 · n=109 · Profil Institut für Stoffwechselforschung GmbH Diabetes Mellitus
tested Change from baseline (week -1) in the number of reflux episodes
result Terminated before completion
Terminated: Too challenging to recruit appropriate participants at an acceptable speed.
RCTNCT02235961Phase 1 · 2014 · n=163 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Number of treatment emergent adverse events recorded
result Completed; results not posted
Kidney Failure, Chronic
tested Plasma glucose during oral glucose tolerance test at week 26
result Withdrawn before enrolment
Withdrawn: Inability to recruit participants
RCTNCT02292290Phase 4 · 2011 · n=99 · University of Leicester Type 2 Diabetes
tested Composite
result Completed; results not posted
RCTNCT02298192Phase 3 · 2014 · n=420 · Novo Nordisk A/S Diabetes
tested Change From Baseline in HbA1c
RCTNCT02299388Phase 4 · 2014 · n=11 · Tulane University School of Medicine Diabetes Mellitus, Non-Insulin-Dependent
tested Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors.
result +0.6 mm/Hg (Change in Systolic Blood Pressure as Measured by A…)
Small sample; effect at the edge of clinical significance.
RCTNCT02315001Phase 2 · 2014 · n=26 · King's College London Ischaemic Heart Disease
tested Change in rate pressure product at 0.1 mV ST-segment depression
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT023248422014 · n=45 · The University of Texas Health Science Center at San Antonio Type 2 Diabetes Mellitus
tested HbA1c at 4 Months
RCTNCT02344186Phase 4 · 2014 · n=12 · Temple University Type 2 Diabetes
tested Changes in unfolded protein response markers
result In progress (unknown)
RCTNCT02351232Phase 2 · 2015 · n=44 · Hvidovre University Hospital Type 1 Diabetes
tested Change in HbA1c
result Completed; results not posted
RCTNCT02403284Phase 4 · 2013 · n=97 · Phoenix VA Health Care System Insulin Resistance
tested Whole Body Insulin Sensitivity (insulin suppression test)
result Completed; results not posted
RCTNCT02408705Phase 2 · 2015 · n=14 · Medical University of Graz Type 1 Diabetes Mellitus
tested Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02417103Phase 3 · 2011 · n=2 · Universitätsklinikum Hamburg-Eppendorf Obesity
tested weight reduction
result Terminated before completion
Terminated: Recruiting failure
RCTNCT02420262Phase 3 · 2015 · n=506 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Glycosylated Haemoglobin)
RCTNCT02443155Phase 2 · 2015 · n=308 · Novo Nordisk A/S Diabetes
tested Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline
result +0.3 Ratio of AUC (Area Under the Concentration-time Curve (AUC) 0-4h…)
RCTNCT02453711Phase 2 · 2015 · n=957 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Relative Change in Body Weight (%)
result −5.5 Percentage (%) of body weight (Relative Change in Body Weight (%))
RCTNCT02461589Phase 2 · 2015 · n=706 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Glycosylated Haemoglobin)
result −0.5 percentage of glycosylated haemoglobin (Change in HbA1c (Glycosylated Haemoglobin))
RCTNCT02472717Phase 2 · 2015 · University Health Network, Toronto Psoriatic Arthritis
tested The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo
result Withdrawn before enrolment
Withdrawn before enrolment; no public reason provided.
RCTNCT02473809Phase 4 · 2015 · n=60 · University of Aarhus Diabetes Complications
tested Change in collagen I cross-linked C-terminal telopeptide measured in serum
result Completed; results not posted
RCTNCT02483299Phase 4 · 2014 · n=40 · University Medical Centre Ljubljana PCOS
tested Change in body weight
result Completed; results not posted
RCTNCT02488057Phase 4 · 2016 · n=360 · Ohio State University Pre-Diabetes
tested Beta Cell Function
result Completed; results not posted
RCTNCT024901762015 · n=50 · Chinese PLA General Hospital Heart Failure
tested a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology
result In progress (unknown)
RCTNCT02492763Phase 2 · 2015 · n=176 · Merck Sharp & Dohme LLC Type II Diabetes Mellitus
tested Change From Baseline in Hemoglobin A1C (A1C) at Week 12
result −1.0 Percent (Change From Baseline in Hemoglobin A1C (A1C) at We…)
RCTNCT02501161Phase 3 · 2016 · n=1012 · Novo Nordisk A/S Diabetes
tested Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification
RCTNCT02501850Phase 4 · 2014 · n=40 · Hospital Universitari Vall d'Hebron Research Institute Diabetes Mellitus Type 2
tested Change in blood levels of Lipoprotein (a) (Lp(a))
result In progress (unknown)
RCTNCT02503943Phase 4 · 2015 · n=90 · Third Affiliated Hospital of Third Military Medical University Type 2 Diabetes
tested Blood Pressure change
result In progress (unknown)
RCTNCT02505334Phase 3 · 2015 · n=635 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c) (Week 26)
result −0.4 Percentage (%) of HbA1c (Change in Glycosylated Haemoglobin (HbA1c) (Week 2…)
Acute ST-segment Elevation Myocardial Infarction
tested a change in the prevalence of no-reflow
result In progress (unknown)
RCTNCT02518945Phase 3 · 2015 · n=26 · University at Buffalo Type 1 Diabetes Mellitus
tested Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.
result −0.7 % HbA1c (Absolute Change After 12 Weeks From Baseline in Me…)
Small sample; effect at the edge of clinical significance.
Metabolism and Nutrition Disorder
tested Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks
result ±0.0 SDS score (Change in Body Mass Index (BMI) Standard Deviation…)
RCTNCT02527993Phase 4 · 2015 · n=11 · Zealand University Hospital Hypoglycemia
tested Changes in blood glucose (mmol/L) assessed by continuous glucose monitoring (CGM).
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02545738Phase 4 · 2015 · n=32 · Steno Diabetes Center Copenhagen Diabetic Kidney Disease
tested Change in albuminuria
result Completed; results not posted
RCTNCT02584582Phase 2 · 2015 · n=10 · Hvidovre University Hospital Type 1 Diabetes
tested Glucagon concentration (postprandial)
result In progress (unknown)
RCTNCT02607306Phase 3 · 2015 · n=819 · Novo Nordisk A/S Diabetes
tested Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira
RCTNCT02611232Phase 2 · 2015 · n=42 · University of Oulu Type 1 Diabetes
tested FPIR (first phase insulin response)
result In progress (unknown)
Type 1 Diabetes
tested The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02638805Phase 3 · 2015 · n=136 · Intarcia Therapeutics Diabetes Mellitus, Type 2
tested Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting
result Completed; results not posted
Obesity
tested Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks
result +63.0 minutes (Gastric Emptying of Solids Half-time (T1/2) at 5 W…)
RCTNCT02650206Phase 1 · 2015 · n=56 · Stanford University Diabetes Mellitus, Type 2
tested Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry).
result Completed; results not posted
RCTNCT02655770Phase 4 · 2016 · n=40 · Rigshospitalet, Denmark Diabetes Mellitus Type 2
tested Change in diastolic properties as assessed by CMR.
result Completed; results not posted
RCTNCT02660047Phase 4 · 2015 · n=51 · Leiden University Medical Center NAFLD / steatotic liver disease — hepatic fat reduction
tested Stroke volume
result Completed; results not posted
RCTNCT02686177Phase 4 · 2016 · n=50 · Assistance Publique - Hôpitaux de Paris Type 2 Diabetes
tested Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group
result Completed; results not posted
Metabolism and Nutrition Disorder
tested Number of treatment emergent adverse events
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Metabolism and Nutrition Disorder
tested Maximum postprandial gallbladder ejection fraction (GBEFmax)
result Completed; results not posted
RCTNCT02730377Phase 4 · 2016 · n=1991 · Novo Nordisk A/S Diabetes
tested Time to Inadequate Glycaemic Control
result +44.0 Weeks (Time to Inadequate Glycaemic Control)
RCTNCT02765399Phase 4 · 2015 · n=23 · Helsinki University Central Hospital Type 2 Diabetes
tested Change in Liver Fat Content
result −1.3 fat % (Change in Liver Fat Content)
Small sample; effect at the edge of clinical significance.
RCTNCT02773368Phase 3 · 2016 · n=420 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Glycosylated Haemoglobin)
Type 1 Diabetes
tested Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin
result −0.2 mM (Difference in Ketone Bodies Formation After Single…)
Type 2 Diabetes
tested Clock Gene expression
result In progress (unknown)
Type 2 Diabetes Mellitus
tested Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period
RCTNCT02832999Phase 4 · 2016 · n=14 · Yaounde Central Hospital Type 2 Diabetes Mellitus
tested Insulin sentivity
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02863419Phase 3 · 2016 · n=711 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Week 26)
result −1.0 Percentage of HbA1c (Change in HbA1c (Week 26))
RCTNCT02870231Phase 1 · 2016 · n=187 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Number of treatment emergent adverse events
result Completed; results not posted
RCTNCT028794092016 · n=150 · Weill Cornell Medical College in Qatar Diabetes Mellitus Type 2
tested Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds
result In progress (active-not-recruiting)
RCTNCT02889510Phase 3 · 2016 · n=76 · Lecube, Albert, M.D. Type 2 Diabetes
tested Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)
result −0.2 % (FEV1) (Changes From Baseline on Measurements of Respirato…)
RCTNCT02898506Phase 2 · 2016 · n=13 · University of Oulu Type 1 Diabetes
tested FPIR (1+3min serum insulin level after iv glucose infusion)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02905864Phase 4 · 2016 · n=150 · Henrik Gudbergsen Osteoarthritis
tested Change in body weight
result Completed; results not posted
RCTNCT02908087Phase 2 · 2016 · n=13 · University of Oulu Type 1 Diabetes
tested Serum C-peptide AUC
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT02909933Phase 4 · 2015 · n=30 · University Medical Centre Ljubljana Polycystic Ovary Syndrome
tested The main outcome was change in body weight.
result Completed; results not posted
RCTNCT02910570Phase 4 · 2016 · n=150 · Parker Research Institute Osteoarthritis, Knee
tested Change in advanced glycation end products in the skin
result Completed; results not posted
RCTNCT02911818Phase 4 · 2016 · n=150 · University of Pennsylvania Obesity
tested Percent Change in Baseline Weight
result −1.5 percent change (Extension Study Primary Outcome: Percent Change in…)
RCTNCT02911948Phase 3 · 2016 · n=210 · Novo Nordisk A/S Diabetes
tested Change in Glycosylated Haemoglobin (HbA1c)
result −1.3 Percentage of HbA1c (Change in Glycosylated Haemoglobin (HbA1c))
RCTNCT02918279Phase 3 · 2016 · n=251 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Change in BMI SDS (Week 0, Week 56)
result −0.2 SDS score (Change in BMI SDS (Week 0, Week 56))
RCTNCT02928614Phase 4 · 2016 · n=150 · Henrik Gudbergsen Osteoarthritis
tested Change in collagen II degradation fragment α-C2M
result Completed; results not posted
RCTNCT02928679Phase 4 · 2016 · n=150 · Henrik Gudbergsen Osteoarthritis
tested Change in the degree of inflammation in the knee-joint (DCE-MRI)
result Completed; results not posted
RCTNCT029302652016 · n=400 · Chinese PLA General Hospital Ischemic Cardiomyopathy
tested main adverse cardiovascular events
result In progress (unknown)
RCTNCT02931383Phase 4 · 2016 · n=150 · Henrik Gudbergsen Osteoarthritis
tested Change in the degree of inflammation in the knee-joint (Greyscale-score)
result Completed; results not posted
RCTNCT02944500Phase 4 · 2016 · n=28 · Beth Israel Deaconess Medical Center Obesity
tested BOLD response to food cues
result In progress (active-not-recruiting)
RCTNCT02953665Phase 2 · 2017 · n=63 · Cedars-Sinai Medical Center Parkinson Disease
tested Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period
result +2.7 units on a scale (Change in Unified Parkinson's Disease Rating Scale…)
RCTNCT02960659Phase 1 · 2017 · n=24 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Type 2 Diabetes
tested Change in Absolute Gluconeogenesis From Baseline to 12 Weeks
result −0.1 mg/kg LBM/min (Change in Absolute Gluconeogenesis From Baseline t…)
Small sample; effect at the edge of clinical significance.
RCTNCT02963922Phase 3 · 2017 · n=396 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Change in Body Weight (%)
result −4.5 Percentage change (Change in Body Weight (%))
RCTNCT02963935Phase 3 · 2017 · n=282 · Novo Nordisk A/S Metabolism and Nutrition Disorder
tested Change in Body Weight (%)
result −3.4 percent change (Change in Body Weight (%))
RCTNCT02964247Phase 3 · 2017 · n=303 · Novo Nordisk A/S Diabetes
tested Change in HbA1c
result −0.7 Percentage of HbA1c (Change in HbA1c)
Type 2 Diabetes Mellitus
tested Change From Baseline in HbA1c to Week 26
result −0.6 percentage of HbA1c (Change From Baseline in HbA1c to Week 26)
Type 2 Diabetes Mellitus
tested Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.
result +0.6 m/s (Differences in Pulse Wave Velocity at Baseline and…)
RCTNCT03011008Phase 4 · 2017 · n=20 · Second Xiangya Hospital of Central South University Type 1 Diabetes Mellitus
tested Mean amplitude of glycemic excursions (MAGE)
result In progress (unknown)
RCTNCT03011021Phase 1 · 2017 · n=40 · Second Xiangya Hospital of Central South University Type1 Diabetes Mellitus
tested Adverse effects
result In progress (unknown)
RCTNCT03018028Phase 3 · 2017 · n=243 · Novo Nordisk A/S Diabetes
tested Change in HbA1c (Week 26)
result −1.2 Percentage point of HbA1c (Change in HbA1c (Week 26))
RCTNCT03034941Phase 4 · 2014 · n=35 · University Medical Centre Ljubljana Obesity
tested The main outcome was change in BMI
result Completed; results not posted
RCTNCT03036800Phase 4 · 2017 · n=392 · University of Leicester Obesity
tested Weight Loss of ≥15% From Baseline (Complete Cases)
result +45.0 Participants (Weight Loss of ≥15% From Baseline (Complete Cases))
RCTNCT03038620Phase 4 · 2017 · n=235 · University of Texas Southwestern Medical Center Obesity, Visceral
tested Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI
result +10.9 percentage of reduction in VAT (Relative Percent Reduction in Visceral Adipose Tis…)
Obesity
tested Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5
result −235 kilocalories (kcal) (Change From Baseline (Visit 3) in Mean Energy Inta…)
RCTNCT03048578Phase 4 · 2017 · n=132 · NYU Langone Health Obesity
tested Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test
result +59.0 percentage of participants (Percentage of Participants Losing at Least 5% Enro…)
RCTNCT03068065Phase 4 · 2014 · n=87 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School NAFLD / steatotic liver disease — hepatic fat reduction
tested Intrahepatic fat
result Completed; results not posted
RCTNCT03087032Phase 4 · 2019 · n=164 · The First Affiliated Hospital of Xiamen University Type 2 Diabetes Patients
tested the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3%
result In progress (recruiting)
RCTNCT03101930Phase 4 · 2017 · n=329 · Vanderbilt University Medical Center Obesity
tested Change in Flow-mediated Dilation
RCTNCT03115099Phase 1 · 2017 · n=80 · Eli Lilly and Company Diabetes Mellitus, Type 2
tested Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
result Completed; results not posted
Obesity
tested Weight
result −3.0 kilograms (Weight)
RCTNCT03158805Phase 2 · 2017 · n=60 · Lindner Center of HOPE Bipolar Disorder
tested Percent Change in Body Weight
result −3.5 % change (Percent Change in Body Weight)
RCTNCT03172494Phase 3 · 2017 · n=720 · Novo Nordisk A/S Diabetes
tested Change in HbA1c
RCTNCT03175120Phase 3 · 2017 · n=453 · Novo Nordisk A/S Diabetes
tested Change in HbA1c
result −0.9 Percentage point of HbA1c (Change in HbA1c)
RCTNCT03182426Phase 1 · 2017 · n=22 · University of Alberta Diabetes Mellitus, Type 1
tested Change of 2-hour mixed meal stimulated C-peptide AUC
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT03191396Phase 3 · 2017 · n=577 · Novo Nordisk A/S Diabetes
tested Change in HbA1c
result +0.6 Percentage of glycosylated haemoglobin (Change in HbA1c)
Diabetes Mellitus, Type 2
tested Change in HbA1c
RCTNCT03260881Phase 4 · 2018 · n=38 · University of Miami Type2 Diabetes
tested EAT Inflammation
result −0.7 ct (cycle threshold) (EAT Inflammation)
Binge-Eating Disorder
tested Binge Episodes
result −1.5 objective binge episodes per week (Binge Episodes)
Terminated: The study was not meeting recruitment goals.
Diabetes
tested Area under the serum insulin degludec concentration time curve
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT03341429Phase 4 · 2018 · n=70 · University College, London Obesity
tested %WL
result Completed; results not posted
Obesity
tested Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system
result Completed; results not posted
Obesity
tested Change in Total Body Weight
result −1.2 percent change (Change in Total Body Weight)
Diabetes Mellitus, Type 2
tested HbA1c
result In progress (unknown)
RCTNCT03426085Phase 2 · 2016 · n=44 · Eastern Virginia Medical School Autonomic Nervous System Diseases
tested Sudomotor Function
result In progress (unknown)
RCTNCT03449654Phase 4 · 2017 · n=102 · Steno Diabetes Center Copenhagen Diabetes Mellitus, Type 2
tested Change in vascular inflammation
result Completed; results not posted
Pulmonary Disease, Chronic Obstructive
tested Transition Dyspnea Index (TDI)
result Completed; results not posted
Pre Diabetes
tested Absolute Body Weight (BW)
result −13.2 kilogram (Absolute Body Weight (BW))
RCTNCT03486392Phase 2 · 2018 · n=474 · Janssen Research & Development, LLC Obesity
tested Percent Change From Baseline in Body Weight at Week 26
result −5.8 Percent Change (Percent Change From Baseline in Body Weight at Wee…)
RCTNCT03500484Early Phase 1 · 2018 · n=13 · Yale University Obesity, Childhood
tested Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.
result Terminated before completion
Terminated: The study was initially paused due to COVID restrictions and then when able to resume, there was no longer funding.
RCTNCT03523273Phase 2 · 2017 · n=136 · Michael Camilleri, MD Obesity
tested Gastric Emptying of Solids (T1/2)
result +85.7 minutes (Gastric Emptying of Solids (T1/2))
Type 2 Diabetes Mellitus
tested Change in Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 4 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of 28 Days of Treatment (Part A Only)
result −106 mmol/L (Change in Hepatic Glycogen Concentration Adjusted …)
RCTNCT03619330Phase 4 · 2014 · n=30 · University Medical Centre Ljubljana Hypogonadism
tested The main outcome was improvements of symptoms related to hypogonadism
result Completed; results not posted
RCTNCT03642600Phase 4 · 2019 · n=21 · Universitaire Ziekenhuizen KU Leuven PCOS
tested weight loss
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT03671733Phase 3 · 2018 · n=150 · Xiangya Hospital of Central South University Obesity
tested Weight Change at 3 months
result In progress (unknown)
RCTNCT03672812Phase 3 · 2018 · n=50 · Hospital de Clinicas de Porto Alegre Brain Death
tested change inflammation
result Completed; results not posted
Smoking Cessation
tested Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date
result ±0.0 Participants (Number of Participants With 7-day Point Prevalence…)
Obesity
tested Number of Participants With Treatment-emergent Adverse Events
result +6.0 Participants (Number of Participants With Treatment-emergent Adv…)
Obesity
tested Compare the changes of pre-prandial fMRI-FCR in Liraglutide 3.0 vs. Placebo Group
result Completed; results not posted
RCTNCT03856047Phase 2 · 2019 · n=706 · Novo Nordisk A/S Overweight
tested Change in Body Weight (%)
result −5.5 Percentage point of body weight (Change in Body Weight (%))
RCTNCT03856632Phase 4 · 2019 · n=60 · University of Miami Atrial Fibrillation
tested Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT)
result In progress (active-not-recruiting)
RCTNCT03883412Phase 4 · 2019 · n=60 · University of Virginia Type2 Diabetes
tested Microvascular Blood Volume - change from baseline
result In progress (recruiting)
RCTNCT039483472019 · n=1708 · First Affiliated Hospital of Jinan University Ischemic Stroke
tested Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)
result In progress (unknown)
Bile Acid Malabsorption
tested Change in stool fequency
result Completed; results not posted
RCTNCT03986008Phase 3 · 2019 · n=60 · Xiangya Hospital of Central South University Obesity
tested Weight Change at 3 months
result In progress (unknown)
RCTNCT04008290Phase 4 · 2020 · n=15 · Universitaire Ziekenhuizen KU Leuven Obesity
tested MMC activity compared between placebo and treatment with liraglutide
result In progress (unknown)
RCTNCT04046822Phase 4 · 2019 · n=70 · Federico II University Obesity
tested Change in gut microbiome composition assessed by Firmicutes-to-Bacteroidetes ratio using Quantitative polymerase chain reaction (PCR)
result In progress (unknown)
Type 2 Diabetes
tested Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months
result Withdrawn before enrolment
Withdrawn: A study start is currently not foreseeable for organizational reasons. Due to the delays, research has also been focused on new compounds, which has reduced the interest in the potential results of the above-mentioned clinical trial.
RCTNCT04074161Phase 3 · 2019 · n=338 · Novo Nordisk A/S Overweight
tested Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg)
result +10.0 Percentage of body weight (Change From Baseline (Week 0) to Week 68 in Body W…)
Obesity
tested Body weight change (kg)
result In progress (unknown)
Diabetic Neuropathic Pain
tested Numerical pain scale (NRS)
result In progress (unknown)
RCTNCT04146155Phase 4 · 2020 · n=200 · Second Affiliated Hospital, Zhejiang University, School of Medicine Type 2 Diabetes
tested Initial and absolute claudication distance
result In progress (unknown)
RCTNCT041864942019 · n=30 · St Vincent's University Hospital, Ireland Sleep Apnea, Obstructive
tested Insulin resistance
result Completed; results not posted
RCTNCT04199728Phase 1 · 2021 · n=27 · Milton S. Hershey Medical Center Opiate Substitution Treatment
tested Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS)
result +8.3 score on a scale (Change in Self-reported Cue-elicited Drug Craving …)
Small sample; effect at the edge of clinical significance.
RCTNCT04311411Phase 1 · 2020 · n=114 · Eli Lilly and Company Obesity
tested Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3
result −534 kilocalories (kcal) (Change From Baseline in Calorie Intake in Particip…)
Gestational Diabetes
tested Incidence of type 2 diabetes
result In progress (active-not-recruiting)
RCTNCT04325581Phase 3 · 2016 · n=16 · Post Graduate Institute of Medical Education and Research, Chandigarh Weight Loss
tested Incretin change
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT04373967Phase 3 · 2020 · n=424 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Type 2 Diabetes
tested glycated hemoglobin (HbA1c)
result In progress (unknown)
RCTNCT04487743Phase 3 · 2020 · n=300 · Xiangya Hospital of Central South University Obesity
tested Mean Change From Baseline in Fasting Body Weight
result In progress (unknown)
RCTNCT04525300Phase 3 · 2020 · n=300 · Xiangya Hospital of Central South University Obesity
tested The composition of the gut microbiota from baseline to end of treatment.
result In progress (unknown)
RCTNCT04531176Phase 4 · 2020 · n=74 · The Cleveland Clinic Type 2 Diabetes
tested Mean Change in Body Weight Between Baseline and 12 Months
result Terminated before completion
Terminated: After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
RCTNCT04535960Phase 2 · 2019 · n=36 · University Health Network, Toronto Type 2 Diabetes Mellitus
tested Proximal tubular natriuresis
result In progress (unknown)
RCTNCT04575844Phase 4 · 2020 · n=80 · University of Virginia Metabolic Syndrome
tested Microvascular Blood Volume - change from baseline
result In progress (recruiting)
RCTNCT04605861Phase 3 · 2020 · n=414 · Shanghai Zhongshan Hospital Obese
tested The percentage of body weight loss
result Completed; results not posted
RCTNCT04657939Phase 4 · 2020 · n=57 · University of Leeds Diabetes Mellitus, Type 2
tested Change in myocardial perfusion after treatment
result Completed; results not posted
Atypical Endometrial Hyperplasia
tested Pathological complete response (CR) rates
result Withdrawn before enrolment
Withdrawn: Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study.
RCTNCT04763564Phase 2 · 2022 · n=8 · University of North Carolina, Chapel Hill Pouchitis
tested Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 4 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline .
result +19.0 percentage reduction of bowel frequency (Mean % Reduction of Bowel Frequency in Percent of …)
Terminated: Due to an interruption in drug supply, the study was terminated
Obesity
tested Relative change in BMI (Body mass index)
result In progress (active-not-recruiting)
Type 2 Diabetes Treated With Insulin
tested Glycemic level
result Completed; results not posted
RCTNCT04881110Phase 4 · 2021 · n=60 · University of Campania Luigi Vanvitelli Type 2 Diabetes
tested Peripheral Transcutaneous Oxygen Pressure
result +10.8 mmHg (Peripheral Transcutaneous Oxygen Pressure)
RCTNCT04903509Phase 1 · 2021 · n=95 · Boehringer Ingelheim Pharmacokinetic / healthy volunteer studies
tested Percentage of subjects with drug-related adverse events
result Completed; results not posted
RCTNCT05029076Phase 1 · 2019 · n=28 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Type 2 Diabetes
tested Maximum (peak) plasma drug concentration(Cmax)
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT05111912Phase 2 · 2021 · n=206 · Sciwind Biosciences APAC CO Pty. Ltd. Obesity
tested Percentage change in participants body weight (%) from the Baseline
result Completed; results not posted
RCTNCT05225974Phase 1 · 2021 · n=32 · The Affiliated Hospital of Qingdao University Therapeutic Equivalency
tested Peak Plasma Concentration (Cmax)
result Completed; results not posted
Diabete Type 2
tested Incidence, nature and severity of adverse events
result In progress (recruiting)
Obesity
tested weight loss
result In progress (unknown)
RCTNCT052853972022 · n=60 · General Committee of Teaching Hospitals and Institutes, Egypt Morbid Obesity
tested Percentage Total weight loss
result In progress (unknown)
RCTNCT05294536Phase 1 · 2020 · n=50 · Sunshine Lake Pharma Co., Ltd. Type 2 Diabetes
tested Maximum (peak) plasma drug concentration(Cmax)
result Completed; results not posted
RCTNCT053135292022 · n=396 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Cognitive function in aging
tested Mild cognitive impairment (MCI) remission rate
result Completed; results not posted
RCTNCT05360147Phase 3 · 2021 · n=30 · Third Military Medical University Type 2 Diabetes Mellitus
tested Changes in cognitive function from baseline to 12 weeks
result Completed; results not posted
RCTNCT05360537Phase 4 · 2021 · n=100 · University of Palermo Diabetes Mellitus, Type 2
tested Change of Time in Range % at 7 days, at 1 and 6 months
result Completed; results not posted
Type 1 Diabetes
tested Weight
result Completed; results not posted
RCTNCT05444569Phase 1 · 2022 · n=47 · Eli Lilly and Company Pharmacokinetic / healthy volunteer studies
tested Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
result Completed; results not posted
RCTNCT05579249Phase 4 · 2023 · n=500 · Novo Nordisk A/S Obesity
tested Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)
RCTNCT05681299Phase 4 · 2023 · n=40 · Columbia University Pharmacokinetic / healthy volunteer studies
tested AgRP change in GH vs. placebo arms
result In progress (recruiting)
RCTNCT057053882023 · n=50 · Emirates Health Services (EHS) Obesity
tested Mean percent total body weight loss at 6 months in each arm of the study
result In progress (unknown)
RCTNCT05767255Phase 3 · 2022 · n=66 · Hospital Universitario San Ignacio Diabetes Mellitus, Type 2 Treated With Insulin
tested To compare the percentage of hypoglycemia
result In progress (unknown)
NAFLD / steatotic liver disease — hepatic fat reduction
tested Blood glucose
result In progress (unknown)
RCTNCT05794581Phase 1 · 2023 · n=32 · Carmot Therapeutics, Inc. Type 1 Diabetes
tested To assess area under the curve (AUC) in glucose metabolism during MMTT
result Completed; results not posted
Polycystic Ovary Syndrome
tested Absolute Body Weight (BW)
result In progress (unknown)
RCTNCT05965908Phase 3 · 2024 · n=150 · Beni-Suef University Polycystic Ovary
tested Body weight loss
result Completed; results not posted
RCTNCT06171152Early Phase 1 · 2024 · n=30 · University of Chicago Multiple Sclerosis
tested Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 8 Weeks
result In progress (terminated)
RCTNCT06361238Phase 3 · 2024 · n=260 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Delirium, Postoperative
tested The incidence of delirium
result In progress (recruiting)
RCTNCT06449703Phase 1 · 2024 · n=44 · Tonghua Dongbao Pharmaceutical Co.,Ltd Pharmacokinetic / healthy volunteer studies
tested Maximum observed plasma insulin degludec concentration
result In progress (unknown)
RCTNCT06501326Phase 4 · 2023 · n=102 · Affiliated Hospital of Nantong University NAFLD / steatotic liver disease — hepatic fat reduction
tested Body weight
result In progress (unknown)
RCTNCT06559722Phase 3 · 2024 · n=510 · Tonghua Dongbao Pharmaceutical Co.,Ltd Type 2 Diabetes
tested Change from baseline in HbA1c after 26 weeks of treatment
result In progress (recruiting)
RCTNCT06742710Phase 4 · 2025 · n=890 · Peking University Third Hospital PCOS
tested Live birth rate associated with single cycle frozen embryo transfer
result In progress (recruiting)
Childhood Obesity
tested Change in BMI SDS
result In progress (recruiting)
RCTNCT06865365Phase 4 · 2025 · n=72 · Medical University of Vienna Obesity, Adolescent
tested % total weight loss
result In progress (recruiting)
Type 1 Diabetes
tested Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment
result In progress (recruiting)
RCTNCT07244003Phase 4 · 2025 · n=430 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. T2DM (Type 2 Diabetes Mellitus)
tested The change of HbA1c compared to the baseline
result In progress (recruiting)
RCTNCT07301437Phase 4 · 2026 · n=120 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine Overweight and Obese Adults
tested weight loss
result In progress (recruiting)
RCTNCT07590219Phase 4 · 2024 · n=30 · University of Sao Paulo General Hospital Severe Obesity
tested Change in Body Mass Index (BMI)
result In progress (active-not-recruiting)
Treatment studies
tested HbA1c change and weight change
result Weight change –0.05 to –1.9%; HbA1c change +0.22% to +0.30% for liraglutide 0.45–0.75 mg, comparable to metformin (+0.09%).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested blood glucose control
result Liraglutide demonstrated efficacy and safety in the LEAD programme compared with placebo and other antidiabetic therapies.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested weight loss
result Controlled SCALE trials showed liraglutide 3.0 mg improves weight loss in obese patients.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested change in HbA1c
result Mean HbA1c change was -1.76% (SD 1.22) with Melitide vs -1.59% (SD 1.31) with Victoza; mean difference -0.18 (95% CI -0.5 to 0.15) meeting non‑inferiority margin.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested C‑peptide area under the curve (AUC) after 52 weeks
result After 52 weeks, 4‑hour C‑peptide AUC was maintained with liraglutide but decreased with placebo (P=.002); total daily insulin dose fell from 0.30 to 0.23 U/kg/day vs rose from 0.29 to 0.43 U/kg/day (P<.001).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Apnea-Hypopnea Index
result Liraglutide reduced AHI by -9.87 events/h (95% CI -19.5 to -0.247, p=0.044) and ODI by -10.16 events/h (95% CI -19.29 to -1.03, p=0.029) versus placebo.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
OpenNCT00873223Phase 1 · 2009 · n=33 · Novo Nordisk A/S Diabetes
tested Insulin detemir pharmacokinetics with and without liraglutide administration
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Diabetes
tested The number of serious adverse drug reactions (SADRs) during the study period
result Completed; results not posted
Diabetes
tested Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%
result Completed; results not posted
Diabetes
tested Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1%
result Completed; results not posted
Type 1 Diabetes Mellitus
tested Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide
result Completed; results not posted
Diabetes
tested Incidence of serious adverse drug reactions (SADRs)
result Completed; results not posted
Diabetes
tested The incidence of SADRs (Serious Adverse Drug Reactions)
result Completed; results not posted
Diabetes
tested Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life)
result Completed; results not posted
Type 2 Diabetes
tested Change in ambulatory blood pressure
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT01507337Phase 1 · 2004 · n=32 · Novo Nordisk A/S Pharmacokinetic / healthy volunteer studies
tested Area under the liraglutide plasma concentration time curve (AUC 0-t)
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT01507389Phase 1 · 2006 · n=24 · Novo Nordisk A/S Diabetes
tested Area under the Curve (0-infinity)
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT01508806Phase 1 · 2005 · n=30 · Novo Nordisk A/S Diabetes
tested Area under the Curve (AUC)
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT01509755Phase 2 · 2000 · n=196 · Novo Nordisk A/S Diabetes
tested HbA1c (glycosylated haemoglobin)
result Completed; results not posted
Pharmacokinetic / healthy volunteer studies
tested Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT01542242Phase 4 · 2012 · n=1 · Vancouver General Hospital Diabetes Mellitus Type 2
tested Hemoglobin A1C
result Terminated before completion
Terminated: Subject withdrew
Diabetes
tested Change in HbA1c between baseline and 6 months
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT015993382011 · n=30 · Centre Hospitalier Universitaire Dijon Type 2 Diabetes Mellitus
tested Change in liking and wanting for protein, lipid and glucid foods
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Diabetes
tested The incidence of SADRs (Serious Adverse Drug Reactions)
result Completed; results not posted
OpenNCT01832532Phase 1 · 2013 · n=34 · Children's Hospital Medical Center, Cincinnati Sleep Apnea
tested Change in Apnea Hypopnea Index (AHI) From Baseline
result +4.2 apnea / hypopnea events per hour sleep (Change in Apnea Hypopnea Index (AHI) From Baseline)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT01856790Early Phase 1 · 2013 · n=15 · Jennifer Sherr Type 1 Diabetes
tested Peak Post-prandial Venous Glucose Levels
result −22.0 mg/dL (Peak Post-prandial Venous Glucose Levels)
Non-randomised; effect size cannot be separated from placebo.
Diabetes
tested Change in HbA1c (glycosylated haemoglobin)
result Completed; results not posted
Diabetes
tested Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction
result Completed; results not posted
OpenNCT02082496Phase 2 · 2014 · n=50 · University of Copenhagen Obesity
tested Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02089256Phase 4 · 2014 · n=10 · University of Tartu Pharmacokinetic / healthy volunteer studies
tested Change in the glucose-sensitivity of the beta cells
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02198209Phase 4 · 2019 · Cedars-Sinai Medical Center Type 2 Diabetes
tested Liver glucokinase activity (acute effect)
result Withdrawn before enrolment
Withdrawn: Investigator decided not to move forward with study prior to study start date
Diabetes
tested Frequency of patients achieving HbA1c reduction of at least 1%-point
result Completed; results not posted
Diabetes
tested Number of AEs (adverse events)
result Completed; results not posted
OpenNCT02516657Phase 3 · 2012 · n=5 · University at Buffalo Type 1 Diabetes
tested Mean Weekly Blood Glucose
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02535299Phase 4 · 2016 · n=200 · Third Military Medical University GLP-1；Metformin；Telomere-telomerase System；Par-4
tested physiological parameter:glycosylated hemoglobin A1c
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
Microvascular Angina
tested Change from baseline in Coronary Flow Reserve
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02616003Phase 4 · 2014 · n=50 · Sana Klinikum Offenbach Morbid Obesity
tested Operability
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02654665Phase 3 · 2014 · n=36 · Changi General Hospital NAFLD / steatotic liver disease — hepatic fat reduction
tested Improvement in NASH
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02674893Phase 4 · 2014 · n=48 · Centre Hospitalier Universitaire Dijon Type 2 Diabetes
tested Modifications in wanting
result Terminated before completion
Terminated: Exploratory protocol, convincing results, robust analysis
OpenNCT02718950Phase 3 · 2016 · n=20 · University of Campinas, Brazil Obesity
tested Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02721888Phase 4 · 2012 · n=127 · Centre Hospitalier Universitaire Dijon Type 2 Diabetes
tested Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes
result Terminated before completion
Terminated: Failure of inclusion
OpenNCT02743598Phase 4 · 2016 · n=4 · Temple University HIV-associated lipodystrophy — visceral fat reduction
tested Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile
result Terminated before completion
Terminated: Lack of funding and time
Diabetes
tested Change in HbA1c (Hemoglobin A1c)
result Completed; results not posted
Obesity
tested Frequency of pancreatitis
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
Monoclonal Gammopathies
tested Change in Epicardial Fat Thickness
result Withdrawn before enrolment
Withdrawn: Lack of funds to cover the costs of the study medications
Metabolism and Nutrition Disorder
tested Number of patients with BMI above or equal to 30 kg/m^2
result Completed; results not posted
Diabetes
tested Incidence of treatment emergent Adverse Events (AEs)
result Withdrawn before enrolment
Withdrawn: Request for the study waived by Indian Health Authorities
OpenNCT03371862Phase 2 · 2017 · Imperial College London Short Bowel Syndrome
tested Improvement in parenteral support
result Withdrawn before enrolment
Withdrawn: No participants recruited. Not able to recruit due to COVID 19.
Obesity
tested Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only)
result Completed; results not posted
OpenNCT035200622017 · n=14 · Nicolai Jacob Wewer Albrechtsen Obesity
tested Volumetric Changes of the Pancreas
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT035343102015 · n=75 · Catholic University of the Sacred Heart Obesity
tested Change of baseline BMI
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Obesity
tested Incidence of adverse events (AEs) by preferred term (PT)
result Completed; results not posted
OpenNCT03632759Early Phase 1 · 2018 · n=16 · Carla Greenbaum, MD Type 1 Diabetes Mellitus
tested Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT03707171Phase 3 · 2018 · n=30 · Third Military Medical University Type 2 Diabetes Mellitus
tested Changes of cognitive function assessed by cognitive function scale after 12 weeks.
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Diabetes Mellitus, Type 2
tested Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)
result Completed; results not posted
ObseNCT038852972019 · n=43 · University Hospitals Coventry and Warwickshire NHS Trust Overweight
tested Weight changes related to treatment
result Completed; results not posted
Diabetes Mellitus, Type 2
tested Change in glycated haemoglobin A1c (HbA1c) (percentage)
result Completed; results not posted
ObseNCT039360492017 · n=168690 · Brigham and Women's Hospital Diabetes
tested Relative hazard of composite outcome of Stroke, MI, and Mortality
result Completed; results not posted
Diabetes Mellitus, Type 2
tested Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis
result −0.2 Events per 1000 person-years (Incidence Rate of Expanded Major Adverse Cardiovas…)
OpenNCT04529278Phase 2 · 2021 · n=18 · Fondation Hôpital Saint-Joseph Diabetes Mellitus, Type 2
tested Weight Loss at Week 26
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT04575194Phase 4 · 2020 · n=40 · National and Kapodistrian University of Athens Obesity
tested Changes in blood pressure
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
Obesity
tested %TWL (%TWL)
result Withdrawn before enrolment
Withdrawn: Cancellation by sponsor
Diabetes Mellitus, Type 2
tested Change in Glycated Haemoglobin (HbA1c)
result Completed; results not posted
OpenNCT04781998Phase 4 · 2021 · n=24 · Anders Fink-Jensen, MD, DMSci Mental Disorder
tested The primary endpoint is the number of "completers"
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT04839237Phase 2 · 2017 · Xiangya Hospital of Central South University Obesity
tested Weight Change at 3 months
result Withdrawn before enrolment
Withdrawn: The sponsor decides withdrawn this study.
OpenNCT04883346Phase 2 · 2021 · n=34 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Obesity
tested Cohen's d (the Standardized Mean Difference)
Non-randomised; effect size cannot be separated from placebo.
Diabetes Mellitus, Type 2
tested Incidence of Adverse Events (AEs) by preferred term
result Completed; results not posted
Type 2 Diabetes Mellitus
tested Incidence of 3-point Major Adverse Cardiovascular Events (MACE)
Obesity or Overweight
tested Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no)
result Completed; results not posted
ObseNCT051621832019 · n=3474 · Brigham and Women's Hospital Diabetes
tested Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up)
result Completed; results not posted
ObseNCT052212292022 · n=29 · University Hospital Birmingham Atrial Fibrillation
tested Adherence to Liraglutide by AF patients before and after first-time ablation [Time Frame- 13 weeks before and 52 weeks after ablation]
result In progress (active-not-recruiting)
Obesity
tested Relative change in body weight
result Withdrawn before enrolment
Withdrawn: No participants enrolled since study start.
OpenNCT05467514Phase 3 · 2022 · n=35 · David Sanchez Garcia Diabetes Mellitus, Type 1
tested To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
ObseNCT057567642023 · n=30 · Louisiana State University Health Sciences Center in New Orleans Obesity
tested weight loss
result In progress (active-not-recruiting)
Type 2 Diabetes Mellitus
tested 3-point MACE
result Completed; results not posted
OpenNCT06201819Phase 4 · 2022 · n=37 · Hospital Civil Juan I. Menchaca Weight Loss
tested Preoperative weight changes
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT06217848Early Phase 1 · 2022 · n=50 · Seoul National University Hospital Panhypopituitarism
tested Change in weight
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
Obesity
tested Incidence of adverse events (AEs) by preferred term (PT)
result Completed; results not posted
OpenNCT06438146Phase 4 · 2024 · n=40 · Brigham and Women's Hospital HIV-associated lipodystrophy — visceral fat reduction
tested Proportion of participants who screen and enroll among those approached
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
Type 2 Diabetes
tested To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Maturity Onset Diabetes of the Young
tested Blood sugar control - HbA1C
result In progress (recruiting)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT07225816Phase 1 · 2025 · n=71 · Novo Nordisk A/S Obesity
tested Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)
result In progress (recruiting)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT07374445Phase 4 · 2023 · n=100 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Obesity
tested Change in %TWL from baseline to endpoint across patient groups
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Treatment studies
tested weight loss, reduced BMI, improved HbA1c
result BMI decreased from 34 kg/m2 to 27.4 kg/m2 and HbA1c fell from 11.6% to 7.5% after liraglutide therapy.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested fasting plasma glucose and postprandial glucose AUC
result Fasting glucose reduced to 6.9 ± 1.0 vs 8.1 ± 1.0 mmol/L (P=0.004); postprandial glucose AUC decreased to 30.6 ± 2.4 vs 39.9 ± 7.3 mmol·L⁻¹·h⁻¹ (P<0.001).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested glycated haemoglobin reduction
result Reduced glycated haemoglobin by ≥1% in type 2 diabetes patients; also caused moderate weight loss and mild blood pressure reduction.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested glycated hemoglobin reduction
result decreasing glycated hemoglobin up to 15 mmol/l
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Pharmacokinetic similarity (AUC, Cmax) between biosimilar and reference
result GMRs were 113.5% for Cmax, 107.2% for AUC0‑t, and 107.0% for AUC0‑∞, all 90% CIs within 80‑125% equivalence range.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested body weight reduction and glycaemia improvement
result Saxenda was effective at reducing body weight and glycaemia in people with obesity and diabetes.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Barrett's esophagus without dysplasia
result Barrett's esophagus without dysplasia occurred in 0.3% of sleeve gastrectomy patients vs 0.1% of liraglutide patients (RR 2.70, 95% CI 1.31-5.56).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested weight, waist circumference, HbA1c, depression, sleep quality, quality of life
result Weight decreased by 2.9% (range -1.0 to -4.5%); waist circumference reduced by 5.6 cm (−8.2 to −2.9); HbA1c fell by 0.3% (−0.4 to −0.2).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested one‑month postoperative inflammatory complications (infection, wound disruption, hematoma, etc.)
result GLP cohort associated with a significantly reduced risk of infection after a procedure, wound disruption, skin/subcutaneous infection, hematoma, and other complications compared with patients without GLP use.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested mouse · Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Glucagon-like peptide-1 analog, liraglutide, alters blood-testis barrier permeability in juvenile healthy rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Liraglutide reduces the apoptosis of feeding and appetite-suppressing neurons in the hypothalamus of obese rats association with the PI3K/AKT/Foxo1 pathway.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.